Alzheimer’s Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts by Fabiani, Camila & Antollini, Silvia Susana
fncel-13-00309 July 17, 2019 Time: 17:32 # 1
REVIEW









University of Giessen, Germany
Aline Stephan,
Université de Strasbourg, France
Jacques Fantini,






This article was submitted to
Cellular Neurophysiology,
a section of the journal
Frontiers in Cellular Neuroscience
Received: 14 February 2019
Accepted: 25 June 2019
Published: 18 July 2019
Citation:
Fabiani C and Antollini SS (2019)
Alzheimer’s Disease as a Membrane
Disorder: Spatial Cross-Talk Among
Beta-Amyloid Peptides, Nicotinic
Acetylcholine Receptors and Lipid
Rafts. Front. Cell. Neurosci. 13:309.
doi: 10.3389/fncel.2019.00309
Alzheimer’s Disease as a Membrane




Camila Fabiani1,2 and Silvia S. Antollini1,2*
1 Instituto de Investigaciones Bioquímicas de Bahía Blanca CONICET-UNS, Bahía Blanca, Argentina, 2 Departamento
de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, Bahía Blanca, Argentina
Biological membranes show lateral and transverse asymmetric lipid distribution.
Cholesterol (Chol) localizes in both hemilayers, but in the external one it is mostly
condensed in lipid-ordered microdomains (raft domains), together with saturated
phosphatidyl lipids and sphingolipids (including sphingomyelin and glycosphingolipids).
Membrane asymmetries induce special membrane biophysical properties and behave
as signals for several physiological and/or pathological processes. Alzheimer’s disease
(AD) is associated with a perturbation in different membrane properties. Amyloid-β
(Aβ) plaques and neurofibrillary tangles of tau protein together with neuroinflammation
and neurodegeneration are the most characteristic cellular changes observed in this
disease. The extracellular presence of Aβ peptides forming senile plaques, together
with soluble oligomeric species of Aβ, are considered the major cause of the synaptic
dysfunction of AD. The association between Aβ peptide and membrane lipids has been
extensively studied. It has been postulated that Chol content and Chol distribution
condition Aβ production and posterior accumulation in membranes and, hence, cell
dysfunction. Several lines of evidence suggest that Aβ partitions in the cell membrane
accumulate mostly in raft domains, the site where the cleavage of the precursor
AβPP by β- and γ- secretase is also thought to occur. The main consequence of
the pathogenesis of AD is the disruption of the cholinergic pathways in the cerebral
cortex and in the basal forebrain. In parallel, the nicotinic acetylcholine receptor has
been extensively linked to membrane properties. Since its transmembrane domain
exhibits extensive contacts with the surrounding lipids, the acetylcholine receptor
function is conditioned by its lipid microenvironment. The nicotinic acetylcholine receptor
is present in high-density clusters in the cell membrane where it localizes mainly
in lipid-ordered domains. Perturbations of sphingomyelin or cholesterol composition
alter acetylcholine receptor location. Therefore, Aβ processing, Aβ partitioning, and
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acetylcholine receptor location and function can be manipulated by changes in
membrane lipid biophysics. Understanding these mechanisms should provide insights
into new therapeutic strategies for prevention and/or treatment of AD. Here, we discuss
the implications of lipid-protein interactions at the cell membrane level in AD.
Keywords: Alzheimer’s disease, Aβ peptide, nicotinic acetylcholine receptor, acetylcholinesterase, cell
membranes, lipid rafts, cholesterol
INTRODUCTION
Biological membranes were, are, and will be complex, dynamic
and controversial. Several different theories/models were
postulated until the fluid-mosaic model was proposed by Singer
and Nicolson (1972). This description of a biological membrane
was very well accepted and gave light about membrane structure
and membrane function. Although a lot of new information
appeared in the following 40 years, the model was able to
survive by absorbing some modifications, as it was emphasized
by Nicolson (2014). Table 1 details and compares the most
important features of the original fluid-mosaic model membrane
(Singer and Nicolson, 1972) and the current vision of a
membrane (Engelman, 2005; Bagatolli, 2010; Goñi, 2014;
Nicolson, 2014).
Nowadays, a membrane is thought of as an increasingly
complex crowded structure of a great variety of lipid and protein
arrangements with lateral and transverse asymmetry, variable
patchiness, variable thickness, and higher protein occupancy
(Engelman, 2005; Nicolson, 2014). It is universally accepted
that biological membranes behave as barriers separating two
fluid media and avoiding contact with each other. But being
a physical barrier is not its only or main function. Many
of the biochemical reactions essential for cell life (metabolic
and signaling reactions involving G-protein coupled receptors
as the rhodopsin or muscarinic receptor and ion channels
as nicotinic, histamine, GABA or glutamate receptors among
others transmembrane proteins) occur in the cell membranes,
making them a truly important agent in almost all cellular
physiological and pathological processes. These reactions imply
molecular communication, which involves protein–protein and
also protein–lipid interactions. Lipid membranes are not just
a “sea” where proteins are embedded, as it was initially
postulated by Singer and Nicolson. Lipids (including fatty acids,
cholesterol, endocannabinoids, arachidonic acid metabolites as
prostaglandins, leukotrienes, and epoxyeicosatrienoic acids, etc.)
are active molecules with important implications. Lipids such as
chol, cardiolipin, PIP2 and glycolipids condition the function of
several transmembrane proteins, a fact reflected in the thousands
Abbreviations: Aβ, amyloid β protein; ACE, acetylcholinesterase; AD,
Alzheimer’s disease; APP, amyloid precursor protein; BACE 1, β-site APP-
cleaving transmembrane aspartic protease 1; CARC, inversed CRAC;
Chol, cholesterol; CRAC, Chol recognition amino acid consensus; DPPC,
dipalmitoylphosphatidylcholine; ld, liquid-disorder domain; LDM, low density
membrane domain; lo, liquid-ordered domain; M1 to M4, nAChR transmembrane
segments; MuSK, muscle specific receptor tyrosine kinase; nAChR, nicotinic
acetylcholine receptor; NMJ, neuromuscular junction; PA, phosphatidic acid;
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PRiMA, proline-rich
membrane anchor; PS1, presenilin 1; PUFA, polyunsaturated fatty acid; SM,
sphingomyelin.
of research papers that report the effect of these lipids on protein
functions (Lee, 2003; Barenholz, 2004; Barrera et al., 2013). Here,
we will discuss the implications of lipid-protein interactions at
the cell membrane level in AD.
CROSSTALK OF ALZHEIMER’S DISEASE
PATHOGENESIS AND LIPID MEMBRANE
Alzheimer’s disease is the most prevalent neurodegenerative
disorder in the elderly, and is characterized by progressive
cognitive decline. The main pathophysiological characteristics
include extracellular accumulation of β-amyloid senile plaques
and intracellular accumulation of neurofibrillary tangles
(hyperphosphorylated microtubule-associated tau protein)
(Feng and Wang, 2012; Kumar et al., 2015). A disruption of the
cholinergic pathways that contribute to the cognitive impairment
of AD patients is described in the cerebral cortex and in the basal
forebrain. AD implicates the formation of extracellular insoluble
peptides derived from the action of two transmembrane
enzymes, a β-secretase (β-site APP-cleaving transmembrane
aspartic protease, BACE 1) and a γ-secretase (an imprecise
multimeric protein complex), on the membrane-bound APP.
Aβ peptides of different lengths, containing 39–42 amino acid
residues, are produced. 1–40 Aβ is produced more frequently
while 1–42 Aβ is the predominant species in senile plaques
(Iwatsubo et al., 1994). They are amphiphilic peptides with
residues 1–28 constituting a hydrophilic domain and residues
29 up to 42 (which correspond to part of the transmembrane
domain of APP), a hydrophobic one (Ji et al., 2002). Whereas
low concentrations of 1–40 Aβ are related to neurotrophic
properties (Yankner et al., 1990; Zou et al., 2002, 2003), 1–42 Aβ,
produced in low amounts under physiological conditions, has a
much higher tendency to form oligomers, protofibrils and fibrils,
which are the ones that constitute AD brain plaques (Jarrett
et al., 1993; Gu and Guo, 2013). The structural-activity relation
between these assemblies and the differences between 1–40 Aβ
and 1–42 Aβ are under continuous investigation and exceed
the aim of this review. Alternatively, APP can be cleaved by
another membrane enzyme (α-secretase) between amino acids
16 and 17 of the Aβ region, avoiding Aβ peptides generation and
producing a neurotrophic and neuroprotective soluble AβPP
(sAβPPα) through a non-amyloidogenic pathway (Thornton
et al., 2006; Wang et al., 2016). In neurons, amyloidogenic and
non-amyloidogenic pathways compete with each other, jumping
between neuroprotection and neurodegeneration (Vetrivel
and Thinakaran, 2006; Tan and Gleeson, 2019). Furthermore,
in normal brains, 1–42 Aβ is produced in low picomolar
concentrations and, as it will be explained later, these low,
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non-toxic concentrations have physiological implications in
synaptic plasticity and memory, among others (Plant et al.,
2003; Puzzo et al., 2008, 2011, 2015). In fact, physiological
1–42 Aβ binds to several target molecules as apoE, the receptor
for advanced glycosylation end products (RAGE), serpin–
enzyme complex receptor (SEC-R) and nicotinic acetylcholine
(nACh) receptors (Turner et al., 2003). Thus, although during
a person’s lifetime there is a continuous formation of all these
peptides, the deregulation of the enzymatic equilibrium with the
consequent accumulation of insoluble peptides is characteristic
of AD. 1–42 Aβ is the most hydrophobic peptide that forms
soluble oligomeric intermediates before aggregating as insoluble
plaques with cytotoxic properties in the AD brains. It induces
iron and cooper reduction in the brain triggering oxidative
stress and damage, it causes calcium homeostasis deregulation
probably through lipid perturbation at the cell membrane, and
it causes oxy-radicals formation and finally neurodegeneration
(Butterfield et al., 2013; Fonseca et al., 2015; Cheignon et al.,
2018). Amyloidogenic and non-amyloidogenic pathways are
thought to occur in different cellular compartments depending
TABLE 1 | Comparison of the main membrane characteristics proposed by the Singer and Nicolson (1972) model and the current cell membrane vision (based on
Engelman (2005), Bagatolli (2010), Goñi (2014), Nicolson (2014), and references there in).
Singer and Nicolson (1972) Today (2019)
The membrane consists of a double layer of lipids (bilayer) in a lamellar
liquid-crystalline phase.
(A preliminary deviation of this concept was included in the original model: “It is
therefore not excluded that some significant fraction of the phospholipid
(perhaps as much as 30 percent) is physically in a different state from the rest
of the lipid.”)
In certain membranes, other phases like liquid-ordered phases or non-lamellar
phases as rhombohedral, tetragonal, inverted hexagonal and cubic phases fulfill
physiologically important functions. These phenomena involve membrane
phase changes that are possible because of the intrinsic deformability of the
membrane. Examples of transient non-lamellar phases can be seen during
membrane fusion where from two independent bilayers originates only one
which involves the coalesce of two bilayers (Chernomordik and Zimmerberg,
1995; Tenchov et al., 2006) or during pore formation by proteins as Bax/colicin
family proteins and actinoporins which involves the formation of non-lamellar
(semi-toroidal or toroidal) lipidic structures (Gilbert et al., 2014; Gilbert, 2016).
The membrane is considered flat. Membranes are usually curved, dynamically modulated by the geometry of both
lipids and proteins, and require asymmetry between both hemilayers in order to
support this membrane curvature (Mouritsen and Bloom, 1984; Epand et al.,
1996; Zimmerberg and Gawrisch, 2006; Bagatolli, 2010).
The protein:lipid ratio is 1.5–4, and thus proteins play an important role in the
membrane structure. However, lipids and proteins do not interact strongly. They
are almost independent entities, without significant perturbation of the bilayer.
(A preliminary deviation of this concept was proposed in the original model: “if it
is proposed that, while the largest portion of the phospholipid is in bilayer form
and not strongly coupled to proteins in the membrane a small fraction of the
lipid is more tightly coupled to protein. With any membrane protein, the tightly
coupled lipid might be specific; that is, the interaction might require that the
phospholipid contain specific fatty acid chains or particular polar head groups.
There is at present, however, no satisfactory direct evidence for such a
distinctive lipid fraction”.)
The membrane is full of proteins, leaving no membrane fraction unaffected by
their presence. Protein–protein interactions have functional important signaling
implications. There are lipids in direct contact with the protein (boundary lipids)
that provide a special lipid environment for the proteins. Some of these lipids
have a fast exchange with bulk lipids (annular lipids), whereas others
(non-annular lipids) are tightly bound to certain membrane proteins stabilizing
their conformation and/or function.
Proteins interact with the bilayer in two different forms: as peripheral or extrinsic
proteins (associated to the lipid bilayer polar headgroups) and as integral or
intrinsic proteins (associated to the hydrophobic matrix).
There are also other proteins that are only part of the time docked to a
membrane (membrane associated proteins). They are not involved in the
microstructure of the membrane; however, they have important membrane
functions and dynamics. For example, protein kinases C and annexins (Bazzi
and Nelsestuen, 1996).
The membranes are fluid. Lipids and proteins have two of three different modes
of motion: rotational around an axis perpendicular to the plane of the
membrane, and freely translational along the plane of the membrane.
Transbilayer diffusion is forbidden because of the energy barrier presented by
the hydrophobic matrix to the polar groups of the lipids and proteins.
The high amount of transmembrane proteins plus peripheral proteins plus
protein-protein interactions restricts dramatically the lateral diffusion of proteins.
The membranes are seen as “more mosaic than fluid.”1 Membrane lipids can
also undergo fast transbilayer diffusion (flip-flop movements), which can be a
protein-helped event or a spontaneous event. Scrambling of lipids contributes
to the dynamic transbilayer asymmetry of the membrane; or, contrary to this, to
losing the asymmetric condition by triggering a signaling process (i.e.,
phosphatidylserine flip-flop from the inner to the outer hemilayer and apoptosis).
The two surfaces of membranes are not identical in composition, structure, and
distribution of oligosaccharides. This asymmetry is based on the forbidden
transbilayer diffusion.
Membranes are asymmetric. Lipids and proteins are different in each hemilayer,
this being a condition that involves lipid transporters or spontaneous lipid
movements (Quinn, 2002; Daleke, 2003; van Meer, 2011). Integral proteins are
naturally asymmetrical in the membrane after their initial biosynthesis.
Asymmetry is essential for cells and its disruption is associated with cell
activation or pathological conditions.
(Continued)
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TABLE 1 | Continued
Singer and Nicolson (1972) Today (2019)
The membrane is mainly homogeneous. The original model
suggested that: “Such short-range order is probably
mediated by specific protein (and perhaps protein-lipid)
interactions leading to the formation of stoichiometrically
defined aggregates within the membrane. However, in a
mosaic membrane with a lipid matrix, the long-range
distribution of such aggregates would be expected to be
random over the entire surface of the membrane”.
The bilayer is full of uneven heterogeneous patches or domains enriched in certain lipids and
proteins, which confer irregular thickness in the membrane. This is the result of certain preference of
protein-lipid contacts, mismatch between the length of the hydrophobic transmembrane segments
of the proteins and the length of the lipid acyl chains, protein–protein contacts, the anchoring of
integral proteins to cytoskeletal proteins, the poor miscibility of certain lipids, etc. These domains
have very important functional implications. Membrane rafts (Simons and Ikonen, 1997) are one
type of membrane domains. They are small (10–200 nm), transient and dynamic (short life,
∼200 ms). These domains, which induce lateral order and heterogeneous organization of
membranes, are a consequence of the immiscibility of certain lipids of biological membranes,
leading to the coexistence of patches with different physical properties and lipid compositions. They
also compartmentalize or segregate certain proteins making more efficient a variety of cellular
processes. Rafts domains in eukaryotic cell membranes are liquid-ordered domains rich in
cholesterol and sphingomyelin. In model membranes, a mixture of lipids that induce a segregation
of liquid-ordered (lo) and liquid-disordered phases (ld) is used to study those domains. A lo phase is
a phase with higher lateral mobility in the bilayer than in a gel phase but with the lipid acyl chains
extended and ordered, whereas a ld phase is a fluid phase with the acyl chains of the lipids highly
disordered and mobile (Simons and van Meer, 1988; Simons and Ikonen, 1997; Brown and
London, 2000; London, 2005; Sonnino and Prinetti, 2013).
The membrane is an isolated system with no exchange of
matter or energy with the environment.
All kind of signals occur in the membrane contacting with the extracellular and intracellular
environment, for example molecules reaching and leaving the membrane in response to stimulus
(Watson, 2015; Wen et al., 2018).
1Nicolson (2014) said: “I have re-termed the model as the ‘Fluid—Mosaic Membrane Model’ to highlight the important role of mosaic, aggregate and domain structures
in membranes and the restraints on lateral mobility of many if not most membrane protein components.”
on secretases localization. γ-secretase complex is present in
multiple compartments: near 6% in the plasma membrane and
the rest in intracellular organelles such as endoplasmic reticulum,
late Golgi/trans-Golgi network and endosomes (Vetrivel et al.,
2004; Chyung et al., 2005). However, α- and β-secretases are
more compartmentalized. α-cleavage occurs at the cell surface
(Parvathy et al., 1999; Haass et al., 2012; Sun and Roy, 2018).
APP is released to the plasma membrane through the secretory
pathway and stays there for a short time. Therefore, during
this short time, APP is proteolytically processed by α-secretase.
Anyway, near 70% of APP is internalized by endocytosis.
A fraction of this APP is recycled to the cell surface and another
one is degraded in lysosomes. BACE 1 is localized late in the
Golgi/trans-Golgi network and endosomes and cleaves APP
during the endocytic/recycling cycle (Koo and Squazzo, 1994);
thus, β-cleavage depends on endocytosis (Koo and Squazzo,
1994; Perez et al., 1999; Huse et al., 2000; Daugherty and Green,
2001; Kamal et al., 2001; Ehehalt et al., 2003) and Aβ is produced
mainly in the trans-Golgi network during the recycling pathway
(Vetrivel and Thinakaran, 2006). Additionally, it was suggested
that 1–42 Aβ is produced mainly in the endoplasmatic reticulum
whereas 1–40 Aβ is produced in the trans-Golgi network
(Annaert et al., 1999; Greenfield et al., 1999).
APP cleavage by secretases always happens in a membrane,
independently of the subcellular compartment. To understand
the importance of this fact, it is recommended to read the
general commentary by Lukiw (2013) in Frontiers in Physiology
titled “Alzheimer’s disease (AD) as a disorder of the plasma
membrane,” whereas the author pointed out the implication
that the membrane has in the physiopathology of this disease.
Several studies postulated that membrane components condition
the APP enzymatic processing. Particularly, Chol is a key
element in the membrane and it has been related to AD in
several ways. Lahdo and De La Fournière-Bessueille (2004)
studied the minimum lipid requirements of a monolayer for
the insertion of APP. They concluded that APP insertion
depends on the Chol content, the Chol/PC and the Chol/SM
ratios, and the monolayer membrane order. They identified
a critical inflection point at near 30% Chol: at a lower ratio
APP localizes in the membrane surface mainly in a β-sheet
conformation, whereas as this Chol percentage increases, APP
can insert spontaneously into the membrane changing its
conformation (Ji et al., 2002; Lahdo and De La Fournière-
Bessueille, 2004). Consequently, once APP is confined to
the interior of the membrane it can perturb the biophysical
properties of this membrane and the activity of several
transmembrane or associated-membrane proteins. The Chol
concentration and Chol location in brain plasma membranes
change throughout a person’s life. At early ages, about 87% of
the Chol is localized mainly in the inner layer of the brain
plasma membrane, but during aging, the percentage of Chol
increases in the outer layer losing the initial transmembrane
asymmetry and reaching at least 30 mol%, the critical value
with respect to APP membrane insertion (Igbavboa et al., 1996;
Wood et al., 2002). In another work, it was suggested that
modifications of Chol compartmentation and the equilibrium
free cholesterol/cholesteryl esters through acyl-coenzyme A:Chol
acyltransferase (ACAT) activation, instead of variations of total
membrane Chol, are the determinant of Aβ accumulation and cell
dysfunction (Puglielli et al., 2001).
The importance of the amount of Chol for APP insertion
leads us to think that APP would probably prefer raft domains
(Cordy et al., 2006; Reid et al., 2007). Initial studies in the brain
showed that both APP and Aβ reside in detergent-insoluble
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glycolipid-enriched membrane domains (DIG) (Lee et al., 1998),
suggesting that those domains are the place in the membrane
where the APP processing occurs. The non-amyloidogenic
pathway through α-secretase is thought to occur in non-raft
domains (Kojro et al., 2001; Reid et al., 2007). On the other
hand, although there is no consensus about the localization of
APP and BACE 1, there is agreement that APP cleavage by β-
and γ-secretase occurs in raft domains (see Table 1 for a detailed
explanation of raft domains). Experiments in culture cells showed
that overexpressed APP and both secretases enzymes localize
in Chol-rich domains (Burns and Duff, 2002; Ehehalt et al.,
2003), and that Chol depletion by Chol synthesis inhibition
or Chol membrane extraction resulted in a reduction of Aβ
production (Simons et al., 1998; Fassbender et al., 2001; Ehehalt
et al., 2003). Several studies suggest that APP is present in
two cellular pools: one in raft domains and another in non-
raft domains. Ehehalt et al. (2003) concluded that this APP
membrane compartmentation explains how the same protein
could be processed in two different ways (generating Aβ in
raft domains and being cleaved by α-secretase in non-raft
domains). Furthermore, they said that although BACE 1 is
present in both raft and non-raft domains it needs to be in raft
domains to be functional, outside these domains the enzyme
is inactive (Figure 1a). That is the reason why, when Chol
diminishes, Aβ production also diminishes but increases αCTF
(C-terminal fragment) or C83, which is a direct product of
α-secretase. Thus, Chol regulates the access of α or β secretase
to APP (Ehehalt et al., 2003). On the other hand, immediately
after this study, a study in human hippocampal membranes
showed that the vast majority of APP is located in non-raft
domains, while β-secretase BACE 1 is found in two cellular
pools: one in raft domains and another in non-raft domains
(Abad-Rodriguez et al., 2004). These authors gave an explanation
opposite to the previous one: when Chol diminishes, which
is what happens in the membrane from AD patients (Mason
et al., 1992; Roth et al., 1995), BACE 1 increases in non-
raft domains and then an enhancement of amyloid peptide
production occurs. They concluded that BACE 1 in raft domains
corresponds to an inactive pool that needs to relocate to
non-raft domains to perform its activity, and that it is the
Chol which directly conditions APP processing by “allowing”
BACE 1 to exit or not from neighboring domains (Figure 1b).
However, they distinguished between a mild membrane Chol
reduction (less than 25%), which results in an increase of
APP processing, and a drastic membrane Chol reduction (more
than 35%), where an overall disruption of membrane integrity
occurs concomitantly with a lower Aβ production. Working
with primary cultures of rat hippocampal neurons infected with
recombinant Semliki Forest virus (SFV) carrying APP, Simons
et al. (1998) arrived to a different conclusion. They showed that
depletion of Chol up to 60–70% did not affect the amount of
APPsec (the main processed form of APP in neurons obtained
by direct α-cleavage), but drastically decreased the amount of Aβ.
Therefore, Chol depletion appears to redirect the APP processing
from amyloidogenic processing to non-amyloidogenic cleavage.
One possible explanation for this is that the small raft-resident
pool of APP and BACE 1 is the active one and that it generates
C99 to be processed by γ-secretase (Rushworth and Hooper,
2011). Another explanation considers that the amount of both
proteins in rafts is so small that the APP processing by BACE
1 is effective once a clustering of raft domains occurs during
endocytosis, meanwhile, in the plasma membrane, APP will be
mainly cleaved by α-secretase through a non-amyloidogenesis
pathway (Ehehalt et al., 2003). Thus, it is possible that APP
processing can be altered by membrane lipid composition
perturbations. Eckert et al. (2003) showed that Chol depletion
decreases the amount of APP in raft domains and, consequently,
the production of Aβ. On the other side, Chol increment as in
Niemann Pick type C model cells, causes an APP augmentation
in raft domains.
A controversial point is where are secretases located, especially
β-secretase, and where they function in the membrane. With
respect to γ-secretase, however, there is broad consensus. It
is postulated that this enzyme is localized in raft domains
confirming that the last step in the generation of Aβ occurs in
those domains (Vetrivel et al., 2005). These authors postulated
that once APP is cleaved by β-secretase, the CTFs (or C99)
produced are recruited or sequestered into raft domains where
cleavage by γ-secretase takes place. They indicated that ∼20% of
BACE 1, less than 5% of APP and more than 70% of CTFs reside
in raft domains; and, based on previous work, they assume that
all cleavage occurs in these rigid domains (Vetrivel et al., 2005).
By magnetic nuclear resonance of C99, Beel et al. (2010)
identified a short sequence of 5 amino acids (VGSNK) between
the extracellular segment and the transmembrane domain that
interacts with Chol, probably through hydrogen bonds. These
authors recognize that although C99 is in raft domains, APP,
which has the same loop, localizes mainly in non-raft domains,
concluding that one possibility is that APP and C99 have different
affinities for Chol. This Chol interaction site is also present
in Aβ peptides, thus explaining the reported Chol-Aβ peptides
interactions that trigger oligomerization, fibrillization, etc. (Beel
et al., 2010) which will be discussed below.
Chol is not only crucial for APP processing in the membrane
by compartmentalizing the location of both APP and secretases,
but also for modulating the secretases activity. Briefly, Chol
positively modulates BACE 1 and γ-secretase activities, and
negatively modulates α-secretase (Bodovitz and Klein, 1996;
Simons et al., 1998; Frears et al., 1999; Kojro et al., 2001; Wahrle
et al., 2002; Ghribi et al., 2006). In lysates from human brain
and in cultured cells, a certain amount of Chol stimulated
β and γ-secretase activities, but at 20 µM Chol γ-secretase
activity was inhibited. It is probable that high Chol can directly
stabilize the activities of the enzymes to the maximum level in
the correct lipid domain or can reduce enzymes degradation
increasing Aβ production (Xiong et al., 2008). Furthermore, APP
processing can be modulated by Chol conditioning membrane
biophysical properties (Kojro et al., 2001; Fukaya et al., 2007;
Kogel et al., 2008; Peters et al., 2009; Yang et al., 2010; Askarova
et al., 2011). For example, substitution of Chol by lanosterol or
polyunsaturated free fatty acids (PUFAs) induced an increment
of membrane fluidity, which was related to an enhancement
of α-secretase activity (Kojro et al., 2001; Yang et al., 2010;
Askarova et al., 2011).
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FIGURE 1 | Schematic diagram showing two distinct hypotheses of APP processing, which differ in the membrane location of the whole process. Two different
colors are used to represent a raft domain and a liquid-disordered domain (light blue and gray, respectively). (a) Hypothesis where β sec is present in both raft and
non-raft domains but needs to be in raft domains to be functional (represented as β sec∗) (Ehehalt et al., 2003). (b) Hypothesis where β sec in raft domains
corresponds to an inactive pool that needs to relocate to non-raft domains to be functional (Abad-Rodriguez et al., 2004). APP, amyloid precursor protein; α-CTF,
C-terminal fragment obtained by α-secretase; α-APPsec, soluble N-terminal APP fragment obtained by α-secretase; Aβ, amyloid β peptide; β-APPsec, soluble
N-terminal APP fragment obtained by β-secretase; AICD, APP intracellular domain obtained by the action of γ-secretase on β-CTF or C99 (intermediate peptide that
is not shown and corresponds to Aβ plus AICD, obtained in the first step by the action of β-secretase); α-sec, α-secretase; β-sec, β-secretase; and γ-sec,
γ-secretase.
Aβ RELATIONSHIP WITH AND
IMPLICATIONS ON CELL MEMBRANE
Chol is also important for Aβ peptide action/effect (Eckert
et al., 2003; Wood et al., 2014). Aβ peptide can adopt different
conformations: a random-coil conformation in aqueous solution,
an antiparallel β-sheet in the core of the amyloid plaques, and an
α-helix in membranes containing Chol (Ji et al., 2002). It can exist
as monomers, oligomers or as amyloid fibrils (Klein et al., 2004;
Reid et al., 2007). Several studies indicate that Chol directly binds
to APP as was described above (Beel et al., 2010), and also to C99
and monomeric Aβ peptides (Barrett et al., 2012), to oligomers
(Ashley et al., 2006), to aggregates (Avdulov et al., 1997), and to
fibrils (Harris, 2008). Considering that the mechanism by which
Aβ produces brain dysfunction in AD patients is still unknown,
these evidences turned the view of Aβ peptides pathogenesis
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from extracellular plaques (the “amyloid theory”: extracellular
amyloid plaques are the responsible for cell death; Hardy and
Higgins, 1992; Haass, 1996; Rushworth and Hooper, 2011;
Serrano-Pozo et al., 2011) to Aβ peptides interaction with
the plasma membrane (Relini et al., 2014). A more recent
explanation indicates that Aβ monomers or small oligomers
are responsible of neuronal death rather than amyloid plaques
as it was previously thought (Irvine et al., 2008; Shankar et al.,
2008). Furthermore, amyloid plaques reduce neuronal death
by sequestering the dangerous Aβ monomers/small oligomers
(Arbor et al., 2016) (Figure 2). This explanation is contrary to
a previous one that considered that Aβ aggregation in β-sheet
conformation, which will finally end as neurotoxic fibrils, is
reduced by Aβ insertion as α-helix after interaction with Chol-
containing membranes (Ji et al., 2002). They showed that both
1–40 Aβ and 1–42 Aβ peptides prefer Chol enriched LDM and
that while in healthy humans the amount of the former peptide
is more than twice the second one, the progression of 1–42 Aβ
deposition runs in parallel with an increase of this peptide in
LDM domains (Oshima et al., 2001; Ji et al., 2002). The authors
concluded that Chol enrichment would be beneficial for reducing
fibrils, a membrane condition opposite to the one found in AD
brains that show a drastic decrease of membrane Chol content
and hence do not have the needed conditions for Aβ insertion,
favoring the dangerous pathway of Aβ aggregation (Ji et al.,
2002). In the case of AD patients, isolated brain membranes
showed a significant decrease in membrane Chol, disfavoring
the insertion of Aβ into the membrane (Mason et al., 1992;
Roth et al., 1995). Thus, Aβ remains in the membrane surface
with a great tendency to aggregation and, ultimately, to plaque
formation (Ji et al., 2002). By confocal laser microscopy and
fluorescence anisotropy, it was shown that 1–42 Aβ peptides
interact with raft domains and that there is an inverse correlation
between Chol content and membrane perturbation (Cecchi
et al., 2009). It was further indicated that a Chol increment
decreases amyloid-induced membrane perturbations at lipid
rafts by altering the physicochemical properties of the domain
(Cecchi et al., 2009). Specific interactions that induce changes
in the lipid bilayer conducing to membrane disruption were
described between lipids and Aβ peptides (Qiang et al.,
2014). Different kinds of interactions were proposed in the
last few years. Vestergaard et al. (2010) performed studies
of Aβ interactions with model biomimetic membranes and
showed that immediately after peptide addition, membrane
fluctuations/morphological changes occur. They suggested that
both Chol levels and lipid composition affect how Aβ oligomers
interact with the membrane. X-ray diffraction studies of the
interaction between a 25–35 Aβ peptide and anionic membranes
enabled the identification of immiscible Chol plaques when
more than 30 mol% Chol was added. The peptide interacts with
the bilayers sequestering more Chol molecules into the plaques
and, hence, decreasing the amount of Chol in the membrane
(Dies et al., 2014).
Chol is not the only important lipid in the Aβ-membrane
interactions, there is also GM1, which is a resident lipid of
raft domains (Lin et al., 2008). High Chol levels facilitate
gangliosides clustering, which is postulated to modulate Aβ
oligomerization. These clusters interact with Aβ peptides in a
concentration dependent manner inducing Aβ aggregation in
β-sheet rich structures with a high Aβ/ganglioside relationship
(McLaurin et al., 1998; Ariga et al., 2001; Kakio et al., 2001,
2002; Matsuzaki, 2007). The binding of Aβ to a GM1 cluster
favors a conformation transition that depends on the protein
density of the membrane. At low peptide/lipid ratios a transition
from random coil to α-helix conformation occurs, whereas at
high peptide/lipid ratios a β-sheet rich structure appears, which
ends in fibrils formation (Matsuzaki et al., 2010; Fukunaga
et al., 2012). Significant alterations in the lipid composition of
raft domains in frontal cortex of AD patients were described
(Martín et al., 2010; Kosicek and Hecimovic, 2013; Fabelo et al.,
2014). A detailed study of the lipid composition of DRM from
temporal and frontal cortex of AD brains indicated that there
was an increment of GM1 and GM2 in both areas of the brain
studied (Molander-Melin et al., 2005). This difference, which was
considered an early event in the progression of AD, was not
observed between samples from brains of different ages or gender
(Molander-Melin et al., 2005). Other studies agree with an age-
dependent high-density GM1 clustering in synaptosomes (Gylys
et al., 2007; Yamamoto et al., 2008) and specific Aβ peptides and
GM1 complexes in early AD brains. GM1-Aβ interactions (GAβ)
were described in the brain and associated with AD pathology
(Yanagisawa et al., 1995; Choo-Smith et al., 1997; Yanagisawa
and Ihara, 1998; Kakio et al., 2001, 2002; Yamamoto et al., 2004,
2005; Wakabayashi et al., 2005). Thus, GM1 is postulated as
the seed for the formation of amyloid fibrils (Staneva et al.,
2018), and several studies considered raft platforms as the
site where these interactions happen. Sasahara et al. (2013)
showed that the interaction and aggregation of the peptide
enhances lipid phase separation because of the GM1 relation
with Aβ aggregates. A two-step phase was postulated to occur
in membranes of AD patients: at early stages the proportion of
GM1 in raft domains increases accelerating Aβ plaques formation
and triggering a gradual raft disruption and perturbation of the
cellular function that involves these membrane domains; at a
later stage, there is also a decrement in Chol content which
prevents Aβ aggregation and increases neurotoxicity (Molander-
Melin et al., 2005). A more detailed study of the mechanism of
Aβ interaction with GM1 indicates that Aβ oligomers, which have
increased hydrophobicity compared to Aβ monomers, primarily
bind to GM1 initiating progressive alterations such as membrane
biophysical and ion permeability perturbations that end in the
well-known synaptotoxic effects of Aβ (Hong et al., 2014).
Although all data points to a direct implication of gangliosides
on Aβ oligomerization, a ganglioside-independent Aβ oligomeri-
zation mechanism was also observed, suggesting that other lipid
components or carbohydrates in raft domains would be also
implicated (Kim et al., 2006).
One important consequence of these raft domains/Aβ peptide
interaction is the occurrence of Aβ peptide aggregation and
Ca+2 channels formation in raft domains (Lin et al., 2001).
In hippocampal cell membranes this process was related to
neurotoxicity (Sepúlveda et al., 2014). Di Scala et al. (2013)
identified a Chol binding domain in a 20–35 fragment of
1–42 Aβ, which is also present in other peptides with high
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FIGURE 2 | Schematic diagram showing three different hypotheses of AD, which are closely related. Two different colors are used to represent a raft domain and a
liquid-disordered domain (light blue and gray, respectively), and also within raft domains, two central lipids are identified for these hypotheses with different colors:
chol and GM1 (green and blue, respectively). Aβ, amyloid β peptide; α7 nAChR, α7 nicotinic acetylcholine receptor.
Chol affinity. Interestingly, although both APP and 1–42 Aβ
interact with Chol, they have distinct binding domains [17–40
Aβ for APP (Barrett et al., 2012) and 20–35 Aβ for 1–42 Aβ
(Di Scala et al., 2013; Fantini et al., 2014)]. By physicochemical
and in silico experiments, it was demonstrated that this
20–35 Aβ domain forms oligomeric Ca2+ channels in the plasma
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membrane in a Chol dependent manner (Di Scala et al., 2014).
The high interaction with Chol of this 20–35 Aβ domain
triggers the helix to an adequate tilted orientation inside the
membrane, which allows accurate peptide-peptide interactions
and the formation of the circular channel. This oligomeric
channel is formed by eight 20–35 Aβ subunits and eight Chol
molecules, with a pore size and an external diameter of 1.46
and 4.4 nm, respectively. The formation of these channels could
help explain the neurotoxic properties of 1–42 Aβ (Figure 2).
Similar in silico studies performed with 1–40 Aβ showed that
the interactions between Chol and peptide are different to those
observed with 1–42 Aβ (Di Scala et al., 2013, 2014). Since
the initial proposal of the existence of transmembrane ion
channels formed by Aβ peptides (Arispe et al., 1993a,b), lots of
studies deepened in the “β-amyloid calcium channel hypothesis”
(Pollard et al., 1995; Kagan et al., 2002; Kawahara, 2010). The
first step for this ion channel formation must be the contact
between the peptides and the membrane. It was demonstrated
that both the lipid composition of the outer membrane and the
structural conformation of the Aβ peptide are crucial for this
interaction. In solution, it was possible to find Aβ as β-sheet,
α-helix or random coil conformations, being the conformational
balance dependent on its concentration. It is postulated that
the presence of certain lipids can shift the equilibrium to one
preferred conformation. Particularly, it was demonstrated that
negatively charged lipids take contact with the peptide by specific
electrostatic interactions (Hertel et al., 1997; McLaurin and
Chakrabartty, 1997; Terzi et al., 1997). Aβ selectively recognizes
and accumulates on GM1-rich membrane domains (Yanagisawa
et al., 1995; Wakabayashi et al., 2005; Yanagisawa, 2005), and
Aβ insertion into the membrane is critically dependent on the
Chol/phospholipids ratio (Ji et al., 2002), as it was detailed
above. More recent works showed that the formation of Ca2+
pores (“annular protofibrils,” Lashuel et al., 2002) in the plasma
membrane is a mechanism dependent on both gangliosides and
Chol. As it was described above, amyloid monomers or soluble
oligomers interact with a ganglioside at the cell surface, with
a specificity that responds to a ganglioside-binding domain for
each amyloid protein (common amino acid residues at specific
locations, with specific variations for each ganglioside), being
the Ca2+ pores significantly diminished in ganglioside deprived
cells (Di Scala et al., 2016). Based on this “calcium-channel
hypothesis” of the AD, a chimeric peptide formed with a minimal
ganglioside-binding domain of α-synuclein and two contiguous
His residues as in 1–42 Aβ (Yahi and Fantini, 2014) avoid pore
formation by 1–42 Aβ. Treatment of WT 5XFAD mice with a
sialic-specific lectin (LFA, Limax flavus agglutinin) significantly
reduced amyloid depositions in the brain, probably by interfering
with the binding of amyloid peptides to gangliosides (Dukhinova
et al., 2019). Furthermore, Cascella et al. (2017) showed
that different oligomer conformations can perturb Ca2+ cell-
permeation by both a channel-independent mechanism as
annular protofibrils, or by a channel-dependent one (through
NMDA-R and AMPA-R).
Aβ peptides that stay in the membrane surface are in a
β-sheet conformation, and once inside the membrane they turn
their conformation to an α-helix (Yu and Zheng, 2012). Other
studies suggested that 1–40 Aβ interacts with the membrane
in two sequential steps. The first one involves the formation
of a pore-like structure and membrane permeation, and the
second one involves subsequent growth of aggregates with fibril
formation and lipid clustering around the fiber which implies
lipid extraction, membrane fragmentation, and loss of membrane
integrity (Engel et al., 2008; Stefani, 2010; Milanesi et al., 2012;
Sciacca et al., 2012; Relini et al., 2013; Kotler et al., 2014).
Recently, Rondelli et al. (2016) described more in detail
the interactions between cell membranes and Aβ peptides.
Those interactions depend on peptide conformation: structural
oligomers are imbibed in the outer hemilayer of the membrane
triggering more Aβ addition and further elongation; on the other
hand, early labile oligomers in equilibrium with monomers are
incorporated as monomers deeply in the membrane coming
up to the inner hemilayer, whereas Aβ organization leads
to pore formation.
A study of the changes induced by 1–42 Aβ on the morphology
and the mechanical stability of model membranes with different
Chol content indicates that Chol drives 1–42 Aβ toward rafts
domains and that at high Chol concentration the presence of
the amyloid peptide did not alter any membrane property, thus
assigning a protective effect against membrane destabilization by
1–42 Aβ to the presence of Chol (Seghezza et al., 2014). Recently,
Staneva et al. (2018) deepened this idea. They observed that 1–42
Aβ has a higher affinity for liquid-disordered (ld) than ordered
(lo) phases, confirming previous results (Ahyayauch et al., 2012).
They concluded that the fraction of Aβ in lo domains, probably
the functionally important one, might be smaller. While in a
lo phase 1–42 Aβ induces practically no changes in the lipid
packing, a significant perturbation of the lipid packing by its
presence was observed in a ld phase. They focus on the presence
of GM1 as a crucial lipid. In ld phases without GM1, the peptide
penetrates and messes up the neighboring lipids. However, in
the presence of GM1 the peptide interacts with the headgroup
of several GM1 promoting a condensing effect and an increased
lipid packing and decreases Aβ penetration. The presence of
GM1 could affect the line tension between lo and ld domains
which in turn affects the kinetics of domains formation, growth,
shape and size. Thus, although it cannot be discarded that the
functional peptide, or at least a minority of it, binds directly to lo
domains, the authors suggested that the fibrillation of Aβ peptides
in raft domains is the consequence of a reorganization modulated
through Aβ peptides in non-raft domains (Staneva et al., 2018).
Not only specific lipid raft characteristics are necessary for
Aβ insertion into the membrane, but also its insertion has
consequences on the membrane (Chang et al., 2017). Several
studies analyzed the membrane biophysical perturbations caused
by Aβ interaction, which could be considered the first step of
its biological effect (Kanfer et al., 1999; Chochina et al., 2001;
Eckert et al., 2003). A decrease in the fluidity of mouse brain
membranes, human lymphocyte membranes and membranes
from rat cortex, hippocampus and striatum was observed in
the presence of 25–35 Aβ and 1–40 Aβ, and in all cases the
effect was dependent on peptide concentration (Müller et al.,
1995). Low concentrations of Aβ significantly perturb membrane
fluidity by specifically altering the acyl-chain mobility of brain
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membranes, an effect dependent on peptide length, with almost
no effect at the polar head groups (Müller et al., 2001). Lately,
it was observed that monomeric 1–40 Aβ has no effect on
membrane fluidity, while oligomeric forms do (Peters et al.,
2009). Contrary to these results, by exposition of hippocampal
neurons to nanomolar concentrations of Aβ oligomers for
24 h we could not observe changes in membrane fluidity
tested with three different fluorescence probes (Uranga et al.,
2017). Peters et al. (2009) showed that membrane perturbation
by Aβ is a consequence of Aβ complexing with GM1; thus,
it is possible that in our experiments the cell membrane
did not have the correct GM1/Chol relationship. A previous
study of the interaction of 1–42 Aβ with planar bilayers had
already demonstrated that the Chol content is directly correlated
with Aβ assembly on the membrane surface, that during this
process membrane changes occur, and that all this process is
governed by lipid bilayer composition (Yip et al., 2002). Thus,
membrane lipid environment modulates Aβ production and
at the same time Aβ causes a membrane perturbation that
positively feedbacks its own production (Peters et al., 2009).
Moreover, Aβ insertion into the membrane not only potentiates
Aβ production but also unspecifically activates a variety of
membrane processes which could eventually end in neuronal
cell death (Kanfer et al., 1999). 25–35 Aβ peptide interacts
with phospholipids through electrostatic interactions favoring
peptide aggregation which causes perturbations at the lipid-
water interphase of the membrane (Martínez-Senac et al., 1999).
Mass spectroscopy studies showed that Aβ inserts into model
membranes containing Chol, but not in the absence of Chol
(Ji et al., 2002). This study also indicated that the membrane
insertion is initiated by the C-terminus of the Aβ peptide which
has the hydrophobic domain.
Brain membranes from middle aged mice were more
susceptible to Aβ perturbations than membranes from aged mice;
and in vitro studies showed that a decrease in membrane Chol
content enhanced Aβ effect, while an increase in membrane Chol
strongly decreased the perturbation effect (Kirsch et al., 2002),
suggesting that Chol protects neuronal membranes from Aβ
perturbations and neurotoxicity (Eckert et al., 2003). However,
they also observed in vivo that a reduction of Chol levels by
approx. 30% by treatment with lovastatin (HMG-CoA-reductase
inhibitor) resulted in moderated membrane alterations without
acyl chain flexibility perturbations and reduced Aβ bulk fluidity
perturbation (Kirsch et al., 2002). A possible explanation is that
Chol membrane modification involves different membrane Chol
pools with different sensitivity for Aβ perturbations whether it is
in vitro or in vivo, with the one at the membrane acyl-chain being
the most receptive (Kirsch et al., 2003).
Another important consequence of an enhanced Aβ produc-
tion linked to lipid membrane is oxidative stress with an excess of
lipid peroxidation and increased lipid susceptibility to oxidative
damage, which exacerbates Aβ toxicity in the membrane (Behl
et al., 1994; Opazo et al., 2002; Cutler et al., 2004; Boyd-
Kimball et al., 2005; Wu and Luo, 2005). It is reported that
Aβ prefers to interact with membranes with high oxidatively
damaged phospholipids (Zampagni et al., 2010), particularly in
raft domains, and that these membranes promote misfolding
and aggregations of Aβ peptides into fibrils (Shringarpure
et al., 2000; Magni et al., 2002; Zhang et al., 2004; Bieschke
et al., 2005; Lee et al., 2006; Murray et al., 2007), whereas
the misfolded peptides promote more oxidative damage in the
membrane, conducing to a positive feedback (Murray et al.,
2007). Aβ increases 4-hydroxy-2-nonenal (HNE) production
which promotes oxidative damage and also induces Aβ to form
β-structure and amyloid fibrils (Mark et al., 1997; Lauderback
et al., 2001; Murray et al., 2005, 2007).
Even though it is not a topic of interest for this review,
it is important to remember that just as Chol is a crucial lipid
molecule for Aβ processing and Aβ membrane effects, the round
trip is also valid since Aβ has an impact on Chol homeostasis
(Koudinova et al., 2000; Michikawa et al., 2001; Gong et al., 2002;
Michikawa, 2003; Koudinov and Koudinova, 2004; Grimm et al.,
2005, 2007). This ultimate effect suggests that Aβ down-regulates
Chol content and also raft content (Beel et al., 2010). Thus,
the peptide behaves as a Chol sensor: when there is high Chol
content in a membrane, the amyloidogenic pathway is favored
and, thus, an enhancement takes place in Aβ processing, which
in turn reduces both Chol uptake and biosynthesis, following up




The basis of AD pathogenesis is still controversial today,
even though several hypotheses try to explain it, such as the
Aβ amyloid cascade (Hardy and Allsop, 1991; Hardy and
Higgins, 1992), the hyperphosphorylated microtubule-associated
tau (Götz et al., 2004), abnormalities of the cholinergic system
(Bartus et al., 1982), oxidative stress (Butterfield and Boyd-
Kimball, 2005), etc. Even though the amyloid hypothesis is the
most popular explanation for the mechanism of AD, it fails
to explain several aspects of this multifactorial etiopathology
(Herrup, 2015). In addition, until now, the majority of clinical
trials conducted to diminish the amount of Aβ did not give good
results (Puzzo et al., 2015; Maia and Sousa, 2019). Although
these failures are not enough to discard the amyloid hypothesis
(see for example Rosenblum, 2014), attention is now focused on
the cholinergic hypothesis since it became the main therapeutic
strategy for this disease (Figure 2). As we will work out in the
following paragraphs, these two hypotheses are highly linked.
The cholinergic system involves two families of receptors,
nAChR and muscarinic acetylcholine receptors (mAChR).
Although both types of receptors are related with cognitive
processes (Ghoneim and Mewaldt, 1977; Petersen, 1977;
Sarter and Paolone, 2011) and are affected in AD, only the
relation between nAChR and AD has been largely studied
(Lombardo and Maskos, 2014).
The nAChR is an integral membrane protein that belongs to
the Cys-loop superfamily of ligand-gated ion channels (Karlin
and Akabas, 1995; Le Novère and Changeux, 1995; Changeux and
Edelstein, 1998; Paterson and Nordberg, 2000). The binding of
its natural agonist acetylcholine triggers a conformational change
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that ends in the opening of a channel and the flux of positive
ions across the membrane, causing membrane depolarization and
a subsequence intracellular cascade of events (Lindstrom, 2003;
Brown, 2006; McKay et al., 2007; Pohanka, 2012). The nAChR
presents a pentameric arrangement, with each subunit having
a large N-terminal extracellular domain, four transmembrane
segments (M1–M4), a small cytoplasmic domain between M3
and M4, and a short C-terminal extracellular domain. To
this day, 16 different nAChR subunits (including: α1-7, α9-
10, β1-4, γ, δ, and ε) that form homologous and heterologous
receptors with distinct structures, functions and locations are
known (Champtiaux et al., 2003; Dajas-Bailador and Wonnacott,
2004; Fucile, 2004; Giniatullin et al., 2005; Gotti et al., 2006a,
2007, 2009; Albuquerque et al., 2009; Shen and Yakel, 2009).
The muscle-type nAChR of the electric organ of Torpedo,
first receptor described and still the prototype of the family,
is formed by α12β1δγ (similar to embryonic muscle nAChR of
vertebrates, which change to α12β1εγ in adult). Two receptor
subtypes are highly expressed in the central nervous system: the
heteropentamer α4β2 nAChR and the homopentamer α7 nAChR
(Schmidt and Freeman, 1980; Sargent et al., 1991; Clarke, 1992;
Sargent and Garrett, 1995; Cooper et al., 1999; Nashmi et al., 2003;
Scholze et al., 2011). The latter is particularly important in AD
(Ma and Qian, 2019). It is present in high density in the striatum,
thalamus, neocortex, and limbic system suggesting a central
role in normal cognition and, hence, in age-related cognitive
decline (Bigl et al., 1982; Mesulam et al., 1983; Muir et al.,
1993; Sarter and Bruno, 1997; Wenk, 1997; Woolf, 1998; Guillem
et al., 2011). It was shown that α7 nAChR is important for
growth, development and aging, regulating the plasticity of the
neural circuit, neuronal differentiation, proliferation, apoptosis
and clearance of aged neurons (Nees, 2015). The levels of this
receptor change during development and adult stage, and in AD
patients, they decrease significantly (Bowen et al., 1976; Perry
et al., 1981, 1985, 1987, 1988; Whitehouse et al., 1981, 1982, 1986;
Coyle et al., 1983; Shimohama et al., 1986; Nordberg et al., 1995;
Paterson and Nordberg, 2000; Auld et al., 2002; Gotti et al., 2006b;
Kim et al., 2013; Ma and Qian, 2019).
Activation of the α7 nAChR opens a high permeability Ca++
channel that consequently activates voltage-dependent Ca++
channels (Perry et al., 1992; Sharma and Vijayaraghavan, 2001)
and triggers an intracellular signaling cascade through activation
of a protein kinase. In the case of activation of presynaptic α7
nAChR, the final event is the fusion of vesicles loaded with
neurotransmitters (glutamic acid, norepinephrine, acetylcholine,
dopamine and GABA) to the presynaptic membrane and the
massive release of these neurotransmitters to the synaptic cleft
(Wonnacott et al., 2006; Ma and Qian, 2019). Postsynaptic α7
nAChR depolarize the postsynaptic membrane and participate in
signal transduction (Messi et al., 1997; Morley and Happe, 2000;
Berg and Conroy, 2002). ACE metabolizes acetylcholine after
its release to the synaptic cleft ending the cholinergic stimulus
(Bowen et al., 1976; Davies and Maloney, 1976; Coyle et al., 1983;
Auld et al., 2002).
The cholinergic hypothesis of AD focuses on the fact that in
brains of AD patients there is a decrease in the total amount of
nAChRs (Whitehouse et al., 1982; Banerjee et al., 2000), which
is an outcome of progressive death of forebrain cholinergic
neurons with an extended cholinergic presynaptic denervation
(Bartus et al., 1982; Court et al., 2000; Graham et al., 2002;
Contestabile, 2011; Hampel et al., 2018). This is considered
a consequence of enhanced Aβ production (Liu and Wu,
2006). Banerjee et al. (2000) observed that in the remaining
cholinergic neurons there was a higher amount of nAChR, which
suggests a possible compensatory mechanism. Many efforts were
performed to ameliorate this loss. However, current approved
pharmacological agents, such as physostigmine, tacrine,
donepezil, rivastigmine and galantamine (Martorana et al., 2010),
are targeted to inhibit ACE function increasing the amount of
acetylcholine at the synapse cleft and ameliorating the clinical
symptoms of AD without halting the progress of the disease.
The affinity of α7 nAChR for 1–42 Aβ is in the low
picomolar concentration, a range estimated to occur in healthy
brains, while the affinity of α4β2 nAChR for 1–42 Aβ is
between 100 to 5000 times lower (Wang et al., 2000a); thus,
it is expected that both α7 nAChR and 1–42 Aβ could
associate under physiological conditions. Puzzo et al. (2015)
hypothesized that under physiological conditions a positive
feedback mechanism occurs: synaptic activity induces Aβ release
that acts as an endogenous ligand and modulates α7 nAChR,
which in turn induces release of neurotransmitters and enhances
synaptic plasticity and memory. Under pathological conditions,
abnormal accumulation of Aβ (nanomolar concentration,
Näslund et al., 1994, 2000; Tapiola et al., 2000; Andreasen
et al., 2003) induces a negative feedback mechanism which
implies inhibition and internalization of α7 nAChR, leading
to synaptic dysfunction and memory loss. The Aβ-α7 complex
influences tau hyperphosphorylation (Wang et al., 2003) and its
internalization leads to plaque formation (Nagele et al., 2003,
2004; Dineley, 2007).
It is thought that the soluble form of Aβ interacts with
α7 nAChR with apparently high affinity (Wang et al., 2000a)
regulating its function (Dineley et al., 2001; Liu et al., 2001;
Pettit et al., 2001). However, there is no consensus about the
nature and consequences of this interaction (Farhat and Ahmed,
2017). While several studies propose an agonist-like effect for
presynaptic nicotinic receptors (Dineley et al., 2002; Dougherty
et al., 2003; Wu et al., 2007; Puzzo et al., 2008; Mehta et al.,
2009; Lilja et al., 2011; Arora et al., 2013), others propose an
inhibitory action (Dineley et al., 2001; Liu et al., 2001; Pettit et al.,
2001; Tozaki et al., 2002; Lee and Wang, 2003; Wu et al., 2004;
Wang et al., 2009; Parri et al., 2011), and others a concentration-
dependent relationship with a stimulatory effect at picomolar Aβ
concentration and an inhibitory effect at high nanomolar Aβ
concentration (Puzzo et al., 2008). The variability between all
the performed studies is so large in terms of in vitro and in vivo
models, Aβ concentrations and Aβ preparations/conformations,
and other conditions, that it is difficult to find a rule for the
data obtained. Khan et al. (2010) gave a possible explanation
for these inconsistency centered in a different Aβ effect on pre
or postsynaptic receptors. Aβ induces a rapid stabilization of an
inactive/desensitized state of postsynaptic receptors, resulting in
an antagonist effect, and a slower desensitization of presynaptic
receptors resulting in an agonist-like effect. The authors pointed
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to differences in the lipid microenvironment of the pre and
postsynaptic α7 nAChR for these different desensitization rates.
Presynaptic terminals have abundance of raft domains, and
experimental disruption of these domains dramatically attenuates
Aβ evoked α7 nAChR currents (Khan et al., 2010). With respect
to the concentration-dependent effect, it is important to take
into consideration that in a normal central nervous system 1–42
Aβ is found, although at low picomolar concentrations. Under
this condition, it is postulated that Aβ exerts a positive effect
on synaptic plasticity and memory formation (Phinney et al.,
2003; Plant et al., 2003; Puzzo et al., 2008, 2011, 2015; Puzzo and
Arancio, 2013). However, in a pathological condition, Aβ cannot
exert its physiological function and hence a feedback mechanism
induces more Aβ production, leading to an enhancement of the
peptide with the subsequent reduction of α7 nAChR with Aβ
removal and synaptic alteration and memory loss (Phinney et al.,
2003; Puzzo et al., 2015).
Interaction of Aβ with α7 nAChR increases Aβ internalization
(Nagele et al., 2002; D’Andrea and Nagele, 2006) and
accumulation in lysosomes causing an excessive intraneuronal
1-42 Aβ accumulation. The majority of the amyloid plaques
proceed from the lysis of degenerated, Aβ-overburdened
neurons (Wang et al., 2000b; Gyure et al., 2001; Langui et al.,
2004; Nunomura et al., 2010; Palop and Mucke, 2010; Li et al.,
2011; Deutsch et al., 2014, 2016). Additionally, the formation of
the Aβ-α7 nAChR complex may influence the membrane lipid
and membrane protein organization (Deutsch et al., 2014, 2016;
Ma and Qian, 2019). At the same time, the internalization of
the Aβ-α7 nAChR complex triggers an upregulation of the α7
nAChR and magnifies the toxicity of the pathology (Molinari
et al., 1998; Xiu et al., 2005; Yu et al., 2005; Liu et al., 2013,
2015; Shen and Wu, 2015) (Figure 2). In AD patients and
preclinical AD models, a high expression of α7 nAChR was
described (Hellström-Lindahl et al., 1999, 2004a,b; Dineley
et al., 2002; Jones et al., 2006; Counts et al., 2007; Ikonomovic
et al., 2009). Chronic exposure to Aβ enhances the expression
of α7 nAChR in neuron and glia cells (Yu et al., 2005; Liu
et al., 2013). Also, an age-dependent increase of cell surface
α7 nAChR was observed in 5xFAD mice, a model that rapidly
develops amyloid pathology (Jin et al., 2015). Several studies
contributed to this hypothesis. Treatment of PC12 cells with
1–42 Aβ increased cell surface α7 nAChR, suggesting that
the peptide induces translocation of the receptor toward the
plasma membrane (Jin et al., 2015). They observed that the
agonist nicotine prevented Aβ induced cell death, whereas the
competitive antagonist α-bungarotoxin potentiates the peptide
effect, indicating that α7 nAChR plays a role in protecting
neuronal cells from Aβ 1–42 peptide (Dziewczapolski et al.,
2009; Wang et al., 2009; Jin et al., 2015). Contrary to this,
Liu et al. (2015) concluded that upregulation of α7 nAChR
induced by Aβ is necessary to mediate peptide neurotoxicity,
both in hippocampal neurons and differentiated cholinergic
SH-SY5Ycells. α7 nAChR function, which is exacerbated by its
upregulation, may be necessary for the toxicity of Aβ aggregates;
this effect was prevented by α7 nAChR inhibition or deletion.
Previous studies showed that the blockade of α7 nAChR
significantly ameliorated attentional deficits (Levin et al., 2013;
Burke et al., 2014). Likewise, the deletion of α7 nAChR gene
was correlated with an improvement in synaptic plasticity
and a reduction in cognitive deficiency (Dziewczapolski et al.,
2009). Two possible cytotoxic α7 nAChR-mediated mechanisms
were proposed: one considers that the α7 nAChR increment
in the membrane conduces to a high calcium permeability,
which could be the ultimate responsible for cell toxicity, and
the other that the high Aβ-α7 nAChR complex internalization
and intracellular accumulation leads to neurotoxicity (Liu et al.,
2015). Thus, while several studies point to α7 nAChR activation
as a beneficial treatment, others suggest that a function inhibition
for a beneficial effect is necessary.
A different hypothesis about Aβ and α7 nAChR relationship
was postulated by Small et al. (2007). They concluded that Aβ
does not bind directly to α7 nAChR but to the lipids of the
plasma membrane, and that the perturbation of the structure or
fluidity of the lipid microenvironment of the receptor could be
the responsible for toxicity through an alteration of the receptor
function. Their conclusion is supported by previous evidence that
showed that Aβ binds strongly to lipids (Subasinghe et al., 2003;
Hou et al., 2005). We will return to this issue later.
We here described the most relevant information about
the interaction between Aβ and α7 nAChR, and its final
consequences, focusing on the events that occur through the
membrane. However, not only the interactions between Aβ
and α7 nAChR are important. Other proteins that interact
with α7 nAChR including Lynx proteins, NMDA-receptors and
the Wnt/β-catenin pathway are important as well. All those
interactions that modulate receptor function are specifically
altered in AD and can lead to differences in the clinical effect
of nAChR ligands in AD (Thomsen et al., 2016). It is also
important to take into account that there is an internal cascade
of signaling downstream α7 nAChR activation that involves
several other active molecules, such as glycogen synthase kinase-
3β (GSK-3β), phosphoinosite 3-kinase (PI3K)-Akt, Wnt and the
mitogen-activated protein kinase (MAPK) signaling pathway,
which are also altered in AD (see Ma and Qian, 2019 for a
further explanation).
The last step in cholinergic signaling is the degradation
of acetylcholine by the enzyme ACE to end the synaptic
transmission. ACE is a globular non-transmembrane protein
that can exist in different molecular forms, depending on the
splicing of the ACE gene (Henderson et al., 2010). Although all
ACE molecular forms and variants have similar catalytic activity,
they also have other non-catalytic, non-classical functions,
which depend on the multiple molecular forms of this enzyme
and on cell types and cellular compartments (Small et al.,
1996; Grisaru et al., 1999; Massoulié, 2002; Hicks et al.,
2011). In non-neuronal tissues, ACE regulates cell proliferation,
differentiation, apoptosis and cell–cell interaction, which is
important to take into consideration when ACE inhibitors for
AD are designed (Lazarevic-Pasti et al., 2017). ACET is the
predominant form in central nervous system, which has a
C-terminal α-helix peptide of 40 amino acids named T peptide.
Through disulphure bondings between these peptides they can
be found as homodimers and homotetramers of ACET. Also,
the T peptide binds to hydrophobic proline-rich domains of
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membrane anchoring-proteins (like collagen-like Q subunit in
NMJ and proline-rich membrane anchor, PRiMA, in the central
nervous system; Massoulié et al., 2005). In the central nervous
system, the majority of ACE is found as tetrameric ACET
(G4) bound to PRiMA (Navaratnam et al., 2000; Perrier et al.,
2002; Massoulié et al., 2005), which constitute the functional
units at cholinergic synapse (Perrier et al., 2002; Dvir et al.,
2010; Henderson et al., 2010; Hicks et al., 2011). PRiMA
could bring the membrane-bound ACE together with other
proteins in specialized membrane areas, such as raft domains,
specifically with α7 nAChR at basal forebrains cholinergic
neurons (Henderson et al., 2005; Hicks et al., 2012). A significant
proportion of ACET is effectively located in raft domains through
a Chol-binding domain of 13 amino acids of PRiMA (a CRAC,
Chol recognition amino acid consensus, sequence), and Chol
depletion or mutations at this domain reduced the lipid raft-
PRiMA association (Xie et al., 2010a,b). A diminution of ACE
activity in the cerebral cortex and other areas in AD patients
was described, being the G4-PRiMA complex the ACE form
markedly altered, whereas the ACE monomeric form was almost
preserved (Atack et al., 1983; Fishman et al., 1986; Sáez-Valero
et al., 1999). Interactions of PRiMA subunit with presenilin 1
(PS1, the catalytic subunit of γ-secretase), which is an aspartyl
protease that cleaves substrates inside membrane, were described
to occur in raft domains (García-Ayllón et al., 2014). This
interaction could explain, in part, the cellular release of ACE
through a shedding mechanism that was postulated to involve
a metalloprotease (Hicks et al., 2013a). Furthermore, a direct
relationship between PS1 and ACE was observed, with an
overexpression of ACE related to higher levels of PS1, ACE
knockdown leaded to decreased PS1 and a mutated PS1 was
related with decreased ACE in the brain (Silveyra et al., 2008,
2012). At the same time, it was also observed that ACE inhibits
AβPP processing through γ-secretase (Niu et al., 2012), perhaps,
acting as an inhibitor of the secretase by interacting with PS1
(Campanari et al., 2014). In AD, ACE activity is diminished
and hence impedes its potentiality to modulate γ-secretase
(Campanari et al., 2014).
Interactions of ACE with Aβ are important in AD (Inestrosa
et al., 1996; Wang et al., 2000b; Small et al., 2007), as the
peptide alters several ACE properties such as its pH optimum
and inhibitor sensitivity (Geula and Mesulam, 1989), making Aβ
even more neurotoxic (Inestrosa et al., 1996; Alvarez et al., 1998).
Moreover, ACE was detected in amyloid plaques evidencing the
high affinity between both molecules and suggesting that ACE
could promote Aβ aggregation (Morán et al., 1993; Inestrosa
et al., 1996). Even more, in some cerebral areas of AD patients
almost all ACE is in these complexes. The binding between
Aβ and ACE occurs at the ACE peripheral anionic site (PAS);
ACE inhibitors that bind to the anionic site (i.e., propidium),
as well as antibodies against it, significantly reduce fibril
formation (Reyes et al., 1997; Bartolini et al., 2003). Although
the ACE catalytic domain does not participate of this interaction
(Inestrosa et al., 1996), new compounds with a dual action
(blocking PAS and catalytic site) are being designed, looking for
the prevention of fibril aggregation with the aim of reversing
the progression of the disease and, at the same time, inhibiting
acetylcholine degradation to ameliorate the symptomatology
(Alptüzün et al., 2010).
Furthermore, a negative relationship between APP
and ACE was observed, as an overexpression of APP repressed
ACE transcription with reductions of both ACE levels and
ACE activity (Hicks et al., 2013b). A similar negative regulation
was observed between APP and PRiMA; however, it is not
clear if there is a direct downregulation by APP or if this
diminution is a consequence of decreased ACE levels (Hicks
et al., 2013b; Nalivaeva and Turner, 2016). The authors proposed
that this ACE downregulation could be a novel neuroprotective
function of APP.
nAChR AND MEMBRANE LIPIDS
As we said in the previous section, there are several nAChR
subtypes depending on the individual pentameric arrangement.
Summing up, all nAChR have two well defined structural
domains: the neurotransmitter-binding site extracellular domain
and the transmembrane domain containing the ion pore.
Whereas the extracellular domain is the site where the agonists or
different activators/inhibitors bind, the transmembrane region,
besides having the ion pore, exhibits extensive contacts with
the surrounding lipids through structural motifs remarkably
conserved along phylogenic evolution (Antollini et al., 2005;
Unwin, 2005; Jha et al., 2007; Baenziger and Corringer, 2011;
Baenziger and daCosta, 2013; Barrantes, 2015). It is well
known that a correct allosteric coupling between both domains
is crucial for nAChR function, strongly dependent on its
surrounding lipid, which modulates the relative proportion of
nAChR in its resting or desensitized states (daCosta et al.,
2002; Baenziger et al., 2000, 2008, 2015; daCosta and Baenziger,
2009; Barrantes, 2010; Barrantes et al., 2010; Hénault et al.,
2015). The most studied nicotinic receptor is the muscle
nAChR, which is not only the paradigm of all other nAChR
but also of the entire cys-loop superfamily. In the following
paragraphs we will discuss the relationship between distinct
lipids or raft domains and the muscle nAChR, knowledge
that can be extended to other members of the family, in
particular to α7 nAChR.
Several years ago, Marsh and Barrantes (1978) described a
layer of immobilized lipids that encircle the muscle nAChR with
characteristics different from those of bulk lipids. Subsequent
studies assigned an important role to these bounded lipids
on muscle nAChR (Criado et al., 1982; Ellena et al., 1983;
Ochoa et al., 1983; Sunshine and McNamee, 1992, 1994;
Narayanaswami et al., 1993; Fernández-Ballester et al., 1994;
Dreger et al., 1997; Barrantes, 2002, 2007; Quesada et al.,
2016). The presence of both Chol and negatively charged
lipids in the nAChR-lipid microenvironment is necessary to
stabilize the nAChR in a functional conformation (Criado
et al., 1984; Fong and McNamee, 1986; Butler and McNamee,
1993; Méthot et al., 1995; Antollini et al., 1996). However, there
is no consensus about if it is the entity/identity of the lipid
itself or the fluidity that each lipid confers to the membrane
the responsible of this role. In spite of this controversy, the
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importance of a proper lipid microenvironment for muscle
nAChR becomes clear when highly hydrophobic molecules,
such as free fatty acids or steroids, perturb nAChR function
through the membrane localizing at the lipid-nAChR interphase
(Andreasen and McNamee, 1980; Villar et al., 1988; Bouzat
et al., 1993; Bouzat and Barrantes, 1996; Nurowska and Ruzzier,
1996, 2002; Minota and Watanabe, 1997; Blanton et al., 1999;
Garbus et al., 2001, 2002; Antollini and Barrantes, 2002, 2016;
Fernández Nievas et al., 2007, 2008). Working with reconstituted
Torpedo nAChR, Jones and McNamee (1988) distinguished
two different populations of lipids in the nAChR-lipid
microenvironment region: annular and non-annular lipids.
Annular lipids interact with the protein in a relatively less
specific manner with a fast rate of exchange with bulk lipids.
Contrarily, non-annular lipids are in close contact with the
protein, probably in between α-helix transmembrane segments
or subunits, and can be associated to lipid binding sites with a
slow exchange rate with bulk lipids (Lee, 2003). We identified
the same two types of lipids in native Torpedo membranes
(Antollini and Barrantes, 1998). The entity/identity of non-
annular lipids are considered crucial for nAChR function;
in the case of annular lipids the biophysical characteristics
are more relevant. This is in concordance with other studies
that assigned several roles to the lipids in a membrane,
two of the main ones being: a collective one, in which they
form a viscoelastic lipid “solvent” with the above-mentioned
heterogeneities; and an individual one as signaling molecules
(Piomelli et al., 2007).
Two annular lipids that are of particular interest are negative
lipids and SM. With respect to the requirement of negative
lipids, PA is particularly of interest. The segregation of PA
domains containing nAChR and the stabilization of a functional
conformation of the receptor by PA were described (daCosta
et al., 2002, 2004; Poveda et al., 2002, 2008; Wenz and Barrantes,
2005; Dickey and Faller, 2008). SM showed moderated affinity for
the nAChR (Bonini et al., 2002) but it is important for proper
nAChR stability in the membrane. Its deficit affects the efficiency
of the nAChR assembly process and the nAChR targeting to the
membrane and increases the rate of turnover (Roccamo et al.,
1999; Baier and Barrantes, 2007). Moreover, SM is important
for membrane biophysical properties as it is asymmetrically
distributed between both membrane hemilayers and it is one of
the main actors of lipid raft domains, being both aspects that
impact on nAChR (Perillo et al., 2016).
A separate paragraph is for Chol, a key lipid for nAChR
(Middlemas and Raftery, 1987). This lipid molecule can be
found in every region of a membrane: as a bulk, annular or
non-annular lipid. In the first two cases, it probably plays
an important function conditioning the physical properties of
the environment, mainly because of its participation in raft
domain formation and in the maintenance of the asymmetrical
membrane condition. As a non-annular lipid, the occurrence of
allosteric binding sites is postulated (Addona et al., 1998). It was
suggested that the binding domain for Chol is at the nAChR
lipid-protein interface, taking contact with the transmembrane
subunits αM4, αM1, and γM4 (Corbin et al., 1998); other studies
identified interactions of Chol with the transmembrane segments
M1, M3, and M4 of each subunit (Hamouda et al., 2006).
By fluorescence quenching and energy-transfer measurements
of T. californica reconstituted membranes, sites accessible to
Chol but not to phospholipids were identified (Narayanaswami
and McNamee, 1993). Using Molecular Dynamics simulations
of the nAChR structure, Brannigan et al. (2008) identified
15 Chol binding sites, large hydrophobic intersubunit and
intrasubunit gaps. The location of Chol molecules at these
sites improved nAChR stability; and in the case of intrasubunit
sites, occupation of these sites by Chol precludes the nAChR
from collapsing. A recent study using coarse-grained molecular
dynamics simulations suggested that while long n-3 chains
(in this case, docosahexaenoic acid, 22:6) have a high propensity
for annular and non-annular sites, displacing Chol and occupying
sites even deeper within the bundle, shorter n-6 chains do not
displace Chol from non-annular sites as efficiently as long n-3
chains (Sharp et al., 2019).
Considering the intimate and close relationship between Chol
and the muscle nAChR, studies looking for a consensus about
specific Chol domains in the nAChR subunits were performed.
A CRAC sequence in a region immediately adjacent to the
M1 transmembrane domain of all the subunits of the muscle
nAChR was identified (Baier et al., 2011). These sequences are
located exiting the membrane bilayer, which suggests that they
are probably not good partners for Chol in the hydrophobic
membrane environment. However, a novel Chol recognizing
domain was identified by in silico studies, a sequence opposite
to a CRAC one (inverted CRAC or “CARC” sequence) at M1,
M3, and M4, which is located inside the membrane and is highly
preserved in the evolutionary scale, from prokaryotes to humans
(Baier et al., 2011; Di Scala et al., 2017). These in silico results were
also experimentally confirmed (Fantini et al., 2016). Furthermore,
the authors concluded that a CARC sequence generally exhibits
more affinity for Chol than a CRAC one (Fantini and Barrantes,
2013), and that it is of high affinity, lipid specific, and saturable
(Fantini et al., 2016).
Chol not only conditions nAChR function but also its
stability in the plasma membrane. There are some controversies
about how the nAChR is organized in the membrane. At the
NMJ, supramolecular aggregations of nAChRs (micron-sized
two-dimensional clusters) are postulated to occur in Chol-
rich lipid microdomains, together with several postsynaptic
proteins including rapsyn, MuSK and Src-family kinases. Chol
would stabilize NMJ and promote its maturation (Willmann
et al., 2006). Depletion of cell-surface Chol produced a marked
alteration of the organization of the nAChR (Kellner et al.,
2007). One hypothesis for this situation is that after an
agrin (extracellular heparan sulfate proteoglycan that aggregates
nAChRs on cultured myotubes) stimulus, nAChR and MuSK
translocate into raft domains where nAChR clustering occurs,
as raft domains concentrate the agrin/MuSK signaling, nAChR
and rapsyn. Disruption of these microdomains by Chol depletion
inhibits agrin stimulation and formation and maintenance of
nAChR clusters (Zhu et al., 2006). A contemporary study
suggested that agrin causes the translocation of nAChR into raft
domains, which is in agreement with the mentioned hypothesis
(Campagna and Fallon, 2006). A slightly different hypothesis
Frontiers in Cellular Neuroscience | www.frontiersin.org 14 July 2019 | Volume 13 | Article 309
fncel-13-00309 July 17, 2019 Time: 17:32 # 15
Fabiani and Antollini Alzheimer’s Disease, Cholinergic System, Membranes
indicates that agrin does not reclute nAChRs into raft domains,
as they are already in those domains independently of agrin
activation, but it triggers the coalescence of raft domains
conducing to nAChR clustering and it is also responsible
for its maintenance, as Chol is necessary for all this process
(Stetzkowski-Marden et al., 2006a,b; Cartaud et al., 2011).
A previous study supports this hypothesis where the authors
observed that nAChR subunits and rapsyn are cotargeted in
the exocytic pathway to the cell surface inserted in Chol-rich
microdomains (Marchand et al., 2002). Furthermore, Chol
depletion affects the maintenance of the nAChR in the plasma
membrane by several mechanisms. Treatments of cells with
methyl-β-cyclodextrin, which extracts Chol from the membrane,
enhanced nAChR internalization by endocytosis with a marked
decrease of the number of nAChR domains, concomitantly
with a gain-of-function of the remaining nAChR (Borroni
et al., 2007; Borroni and Barrantes, 2011; Kamerbeek et al.,
2013). Furthermore, chronic treatments with mevinolin, an
inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase and
hence of Chol synthesis, inhibited the trafficking of the receptor
toward the membrane surface, which caused low nAChR cell-
surface expression, and increased the intracellular nAChR pools
(Pediconi et al., 2004). Moreover, Chol conditions muscle
nAChR cell-surface diffusion (Baier et al., 2010; Mosqueira
et al., 2018) and nAChR stability in confined raft domains
(Mosqueira et al., 2018).
Different results of the interaction between muscle nAChR
and lipid domains were obtained in model systems. We
observed that reconstituted Torpedo nAChR in symmetric
model membranes with coexistence of liquid-ordered (lo) and
liquid-disordered (ld) domains was distributed homogeneously,
without preference for any domain (Bermúdez et al., 2010).
However, similar experiments with a synthetic peptide
corresponding to the γM4 peptide showed a marked preference
of this peptide for lo domains (de Almeida et al., 2004; Bermúdez
et al., 2010). Thus, although this transmembrane segment could
give the nAChR the potentiality to localize in raft domains,
it is not sufficient and other conditions must occur which
influence nAChR partition profile. One of these mentioned
conditions is membrane asymmetry. By increasing SM in the
outer hemilayer, we observed an increment of the Torpedo
nAChR in lo domains, and the same was observed when specific
SM species instead of brain SM were used in symmetric models
(Perillo et al., 2016). Recently, by using coarse-grained molecular
dynamics simulations of nAChR inserted in a ternary system
of DPPC:Chol:PE or PC with PUFA, the authors concluded
that nAChR partitioned in ld domains poor in Chol (Sharp
et al., 2019). The simulated membrane, despite having lo and ld
domains, (a) did not have SM of any species, which is a critical
lipid for raft domains in biological membranes, (b) used PUFA
which are known to behave as nAChR inhibitors probably by
competition with Chol for non-annular sites, as the authors
observed in the study, and (c) was symmetric, a condition
different to the natural asymmetry of biological membranes.
Thus, this work emphasizes that it is not just the presence of an lo
domain, but also its physicochemical characteristics and specific
lipid components which condition nAChRs agglomeration.
With respect to neuronal nAChR, it was observed that
α7 nAChR is associated with Chol-rich microdomains at
somatic spine-rich regions of ciliary neurons and that the
FIGURE 3 | Schematic diagram of a plasma membrane, depicting the spatial relationship between the molecules involved in Aβ synthesis and the cholinergic
system. Two different colors are used to represent a raft domain and a liquid-disordered domain (light blue and gray, respectively). APP, amyloid precursor protein;
Aβ, amyloid β peptide; α7 nAChR, α7 nicotinic acetylcholine receptor; ACET, tetrameric acetylcholinesterase; α-sec, α-secretase; β-sec, β-secretase; γ-sec,
γ-secretase; and PRiMA, proline-rich membrane anchor.
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maintenance of these receptors within these domains is Chol-
dependent (Brusés et al., 2001). Furthermore, in PC-12 cells,
a rat pheochromocytoma cell line, α7 nAChR location in raft
domains is necessary to regulate cAMP signal through the
nicotinic activation, signaling that was altered by Chol depletion
(Oshikawa et al., 2003). A similar relation between α7 nAChR
location at raft domains and efficiently signaling, with a direct
Chol influence, was also observed in CG neurons (Liu et al.,
2008). Disruption of raft domains in the same CG neurons
increased the mobility of α7 nAChRs in the synaptic space
(Fernandes et al., 2010). Disruption of raft domains by removal of
Chol and/or SM in rat primary hippocampal neurons slowed the
kinetics of α7 nAChR desensitization through increasing the rate
of recovery from desensitization and increased the agonist affinity
and single-channel conductance (Colón-Sáez and Yakel, 2011).
The authors observed the effects of raft domains disruption also
on α3β2 nAChRs functionality. These results confirm that, as
with muscle nAChR, neuronal nAChR functionality is modulated
by its lipid microenvironment with the raft domains integrity a
critical factor. On the contrary, α7 nAChR at non-neural tissues,
in rat arterial endothelial (RAEC) and human venous endothelial
(HUVEC), was found to occur in non-raft subcellular membrane
fractions (Peña et al., 2011).
CONCLUSION
Alzheimer’s disease is a progressive neurodegenerative condition,
the etiopathogenic mechanisms of which are not totally
understood. Due to its multifactorial character, the development
of new drugs and effective treatments is still a challenge (Dineley,
2007). Here, we intended to focus only in the processes related
to this disease that occur in the cell membrane, which allows
to observe the multiple crosslinking between specific lipids and
the membrane proteins involved in the amyloid process. In
a dry human brain, half of its weight corresponds to lipids,
molecules with great chemical diversity and complex dynamical
heterogeneities (Piomelli et al., 2007). Thus, it is not surprising
that through the years more and more biological functions
are being related to them. Raft domains are implicated in
several of the events involved in AD. Chol is a very important
lipid at synaptic membranes (Barrantes, 2007) and it is also
a principal author in AD, together with other lipids such as
GM1, SM or PA. It is not surprising that APP, Aβ, nAChR
and G4-PRiMA all have Chol-recognition amino acid sequences.
Although there are still some controversies, there is no doubt
that APP processing, Aβ production and Aβ action are intimately
related to raft domains, and that the cholinergic system function
is highly conditioned by both raft domains and Aβ. A continuous
crosstalk between amyloid processing and cholinergic signaling
occurs at physiological and pathological conditions, and shifting
from one condition to the other is triggered by an imbalance
in Aβ synthesis, being Chol homeostasis intimately implicated
(Figure 3). Currently, the only available treatment for AD is
a group of drugs that inhibit ACE. A better understanding of
Aβ-α7 nAChR interactions and of the implication of Chol in
particular, and membrane heterogeneities in general, could allow
for a deepening of the understanding of this neurodegenerative
pathology and could help define new therapeutic strategies and
potential novel molecular targets.
The World Health Organization (WHO) declared dementia
as a public health priority (in Priority Medicines for Europe
and the World "A Public Health Approach to Innovation" by
Saloni Tanna). The number of people worldwide with this
condition is in continuous growth: whereas in 2010 this number
was estimated to be 35.6 million, it is expected to be near
115.4 million in 2050, in line with the view that this number
nearly doubles every 20 years. AD is the most common form
of dementia and, hence, it has become a major public health
problem because of the continuous increase in the age of
the population (in fact, in 2050 it is expected that 22% of
the world population will be aged 60 and over). Thus, it is
imperative to count with specific biomarkers for early stages
of the disease, to improve detection and evaluation and, of
course, with effective therapies. At present, the only treatment
available is symptomatic: ACE inhibitors, like physostigmine,
tacrine, donepezil, rivastigmine, and galantamine. Although new
knowledge is continuously emerging, until now and as suggested
in this work, there is no consensus among the different coexisting
hypotheses around this subject, several of which are antagonistic.
This fact clearly contributes to the current situation: there is not
a single specific AD treatment commercially available. A great
variety of molecular targets were proposed for AD treatment,
a few of which were explained here (like β and γ-secretases,
α7 nAChR and ACE), and plenty of studies have been conducted
on them. Much effort has been invested in this area, but more
is still required. Science is facing a huge challenge. Further
studies that contribute to the description and explanation of the
AD etiopathology will be crucial for a final consensus on AD.
Multitarget-drug design is an interesting strategy as AD involves
a large number of different molecules. And finally, it should not
be forgotten that membrane lipids are not just a “sea” where
proteins function but, as explained in detail above, they are
necessary for the proper function of these proteins. Chol, GM1,
SM, among others, are important lipids for AChR function,
conformation and membrane stabilization, and also for Aβ
processing and Aβ-membrane insertion. Thus, lipid membrane
perturbation, and hence, raft domains alteration and membrane
signal perturbation, directly impact in several hot points of AD
etiopathology and, for this reason, they can also be considered as
interesting molecular targets for AD.
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